ASS1 and breast carcinoma: To this end, Yao et al. [77] conducted a phase 1 study of ADI-PEG20 in combination with liposomal doxorubicin for ASS1-negative metastatic solid cancers, focusing on HER2-negative breast cancer where anthracyclines have a key role [77].